Compounds > cacalol
Page last updated: 2024-12-08

cacalol

Description

cacalol: a sesquiterpene contained in Cacalia delphiniifolia Sleb et Zucc; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID181105
CHEMBL ID452935
SCHEMBL ID3134482
MeSH IDM0481628

Synonyms (8)

Synonym
cacalol
(5s)-3,4,5-trimethyl-5,6,7,8-tetrahydrobenzo[f][1]benzofuran-9-ol
CHEMBL452935
24393-79-1
naphtho(2,3-b)furan-9-ol, 5,6,7,8-tetrahydro-3,4,5-trimethyl-, (s)-
SCHEMBL3134482
DTXSID40947263
3,4,5-trimethyl-5,6,7,8-tetrahydronaphtho[2,3-b]furan-9-ol

Research Excerpts

Overview

Cacalol also proved to be a potent neuroprotective substance which could protect neuronal hybridoma N18-RE-105 cells from L-glutamate toxicity.

ExcerptReferenceRelevance
"Cacalol is a sesquiterpene with anti-inflammatory potential that is isolated from"( Cacalol Acetate, a Sesquiterpene from
Alarcón-Aguilar, FJ; Almanza-Pérez, JC; Gomez-Quiroz, LE; Jiménez-Estrada, M; Mora-Ramiro, B; Rosiles-Alanis, W; Ventura-Gallegos, JL; Zentella-Dehesa, A, 2020)		2.72
"Cacalol also proved to be a potent neuroprotective substance which could protect neuronal hybridoma N18-RE-105 cells from L-glutamate toxicity."( Potent antioxidative activity of cacalol, a sesquiterpene contained in Cacalia delphiniifolia Sleb et Zucc.
Iga, M; Kimura, M; Shindo, K, 2004)		1.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID380821Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as food intake per mouse at 1000 mg/kg, po administered as single dose1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
AID359481Antimicrobial activity against Candida albicans ATCC 102312001Journal of natural products, Apr, Volume: 64, Issue:4
New modified eremophilanes from the roots of Psacalium radulifolium.
AID359480Antimicrobial activity against Proteus mirabilis ATCC 124532001Journal of natural products, Apr, Volume: 64, Issue:4
New modified eremophilanes from the roots of Psacalium radulifolium.
AID380827Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as body weight per mouse at 1.09 mmol/kg, po administered as single dose for 24 hrs1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
AID359477Antimicrobial activity against Staphylococcus aureus ATCC 278532001Journal of natural products, Apr, Volume: 64, Issue:4
New modified eremophilanes from the roots of Psacalium radulifolium.
AID380819Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as body weight per mouse at 1000 mg/kg, po administered as single dose for 24 hrs1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
AID380825Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as changes in plasma glucose level at 1.09 mmol/kg, po administered as single dose for 24 hrs1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
AID359482Toxicity against Artemia salina2001Journal of natural products, Apr, Volume: 64, Issue:4
New modified eremophilanes from the roots of Psacalium radulifolium.
AID359478Antimicrobial activity against Escherichia coli ATCC 89372001Journal of natural products, Apr, Volume: 64, Issue:4
New modified eremophilanes from the roots of Psacalium radulifolium.
AID380829Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as food intake per mouse at 1.09 mmol/kg, po administered as single dose1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
AID380817Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as changes in plasma glucose level at 1000 mg/kg, po administered as single dose for 24 hrs1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
AID380816Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as changes in plasma glucose level at 1000 mg/kg, po administered as single dose for 3 hrs1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
AID1674505Anti-inflammatory activity in TPA-induced CD-1 mouse ear edema model assessed as inhibition of ear edema at 1 mg relative to control2020Journal of natural products, 08-28, Volume: 83, Issue:8
Cacalol Acetate, a Sesquiterpene from
AID1674504Anti-inflammatory activity in TPA-induced CD-1 mouse ear edema model assessed as ear weight at 1 mg2020Journal of natural products, 08-28, Volume: 83, Issue:8
Cacalol Acetate, a Sesquiterpene from
AID359479Antimicrobial activity against Pseudomonas aeruginosa ATCC 278532001Journal of natural products, Apr, Volume: 64, Issue:4
New modified eremophilanes from the roots of Psacalium radulifolium.
AID380824Antihyperglycemic activity in C57BL-6J ob/ob mouse type 2 diabetic model assessed as changes in plasma glucose level at 1.09 mmol/kg, po administered as single dose for 3 hrs1999Journal of natural products, Aug, Volume: 62, Issue:8
Antihyperglycemic sesquiterpenes from Psacalium decompositum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's6 (54.55)29.6817
2010's3 (27.27)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.09 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
celecoxib
[no description available]		2.2510organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
diazoxide
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.		2.0510benzothiadiazine;
organochlorine compound;
sulfone		antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent
glyburide
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.		2.0510monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.2510aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		210guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
phenylephrine
Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.		2.0510phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		2.0210glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.0610taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		2.0310D-glucopyranoseepitope;
mouse metabolite
sesquiterpenes
[no description available]		3.6790
bay 11-7085
BAY11-7085 : A sulfone that is benzene substituted by [(E)-2-cyanoethenyl]sulfonyl and tert-butyl groups at position 1 and 4, respectively. It is an irreversible inhibitor of IkappaB-alpha phosphorylation in cells (IC50 = 10 muM) and prevents the activation of NF-kappaB.		2.2510benzenes;
nitrile;
sulfone		anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
ferroptosis inducer;
NF-kappaB inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		0210
Diabetes Mellitus, Adult-Onset
[description not available]		0210
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		0210
Innate Inflammatory Response
[description not available]		02.1710
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.1710
Breast Cancer
[description not available]		07.0610
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0610
Anasarca
[description not available]		02.0310
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.0310
chemdatabank.com